Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Epidemiology of Congenital Heart Disease in France (EPIDEMIO-CHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04740177
Recruitment Status : Completed
First Posted : February 5, 2021
Last Update Posted : March 16, 2021
Sponsor:
Collaborators:
National Reference Center for Complex Congenital Heart Disease, Marie-Lannelongue Medical and Surgical Center, Le Plessis Robinson
National Reference Center for Complex Congenital Heart Disease, University Hospital of Bordeaux
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:

Congenital heart disease (CHD) is the leading cause of birth defects, with an incidence of 0.8%. Since the 1980s, France has been a pioneer in neonatal CHD surgery (Pr. Fontan, Pr. Lecomte, Pr. Serraf, etc.), in prenatal diagnosis, and in interventional cardiac catheterization.

Actually, first children operated for complex CHD have reached adulthood and a new epidemiology of CHD is emerging. Currently, one of the public health challenges is the need to maintain appropriate follow-up and to avoid disruption of care during the transition from adolescence to adulthood. Thus, the national health authorities (DGOS) recently certified a national network of expert centers for complex CHD (M3C).

In addition, under the leadership of the French Society of Cardiology, the sub-specialty of Pediatric and Congenital Cardiology has been recognized.

However, while North American and North European countries have published their updated data on the main indicators of CHD morbidity and mortality, no study has reported epidemiology of CHD in France.

Currently, available data are approximate, estimating that 200,000 children and 250,000 adults would be living in France with a CHD. Nevertheless, no information is available on hospitalizations, type of CHD, their follow-up, possible disruption in care, and morbidity and mortality in patients with CHD in France. This epidemiological study will use the national health insurance hospital database to answer these questions.


Condition or disease
Congenital Heart Disease

Detailed Description:

Retrospective epidemiological study based on the national health insurance hospital database from 2010 to 2020 (10 years):

Main objective:

• To assess the prevalence of patients with CHD hospitalized in France over 10 years.

Secondary objectives: asess over the same period:

  • Overall mortality rate according to the CHD classification and the geographic area
  • Overall morbidity rate, according to the CHD classification and the geographic area
  • Overall cardiac surgery-related mortality rate (cardiac surgery and other surgery), according to the CHD classification (adjusted for the severity of the CHD and the surgical procedure) and to geographic area
  • Overall cardiac catheter-related mortality rate, according to the CHD classification (adjusted for the severity of the CHD and the catheterization procedure) and to geographic area
  • CHD follow-up within and outside the national M3C network
  • Periods of loss of cardiological follow-up (within or outside the M3C network, in hospital or in town)
  • Obstetrical data for women (parity, pregnancy)
  • The existence of a prenatal diagnosis (yes / no and the term of pregnancy at the time of diagnosis of CHD)

Layout table for study information
Study Type : Observational
Actual Enrollment : 450000 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Epidemiology of Congenital Heart Disease in France : EPIDEMIO-CHD
Actual Study Start Date : February 1, 2020
Actual Primary Completion Date : December 1, 2020
Actual Study Completion Date : December 30, 2020

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Rate of patients with CHD hospitalized in France [ Time Frame: 10 years ]
    Rate of patients with CHD hospitalized in France


Secondary Outcome Measures :
  1. Rate of mortality in patients with CHD [ Time Frame: 10 years ]
    Rate of mortality in patients with CHD

  2. Rate of cardiac surgery-related mortality in patients with CHD [ Time Frame: 10 years ]
    Rate of cardiac surgery-related mortality in patients with CHD

  3. Rate of cardiac catheter-related mortality in patients with CHD [ Time Frame: 10 years ]
    Rate of cardiac catheter-related mortality in patients with CHD

  4. Rate of CHD patient's loss to follow-up within and outside the national M3C network [ Time Frame: 10 years ]
    Rate of CHD patient's loss to follow-up within and outside the national M3C network

  5. Rate of CHD prenatal diagnosis [ Time Frame: 10 years ]
    Rate of CHD prenatal diagnosis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient with congenital heart disease (CHD)
Criteria

Inclusion criteria:

- Patient (of any age) with a CHD as defined by the international ACC-CHD classification and listed in the ICD10 classification, hospitalized from 01/01/2010 to 12/31/2019 in a French tertiary care hospital from the M3C network.

Exclusion criteria:

- Patient with non-malformative genetic heart disease (cardiomyopathy, hereditary rhythmic disease).


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04740177


Locations
Layout table for location information
France
Uh Montpellier
Montpellier, France, 34295
Sponsors and Collaborators
University Hospital, Montpellier
National Reference Center for Complex Congenital Heart Disease, Marie-Lannelongue Medical and Surgical Center, Le Plessis Robinson
National Reference Center for Complex Congenital Heart Disease, University Hospital of Bordeaux
Investigators
Layout table for investigator information
Study Director: Pascal AMEDRO, MD-PhD UH MONTPELLIER
Principal Investigator: Sarah Cohen • Centre Médico-Chirurgical Marie-Lannelongue, Le Plessis Robinson
Principal Investigator: Jean-Benoit Thambo University Hospital, Bordeaux
Layout table for additonal information
Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT04740177    
Other Study ID Numbers: RECHMPL20_0119
First Posted: February 5, 2021    Key Record Dates
Last Update Posted: March 16, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: NC

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Montpellier:
Congenital heart disease
Paediatric cardiology
Epidemiology
M3C network
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Heart Defects, Congenital
Cardiovascular Diseases
Cardiovascular Abnormalities
Congenital Abnormalities